1 Department of Internal Medicine, Hypertension and Vascular Diseases Medical University of Warsaw Poland.
J Am Heart Assoc. 2019 Feb 19;8(4):e010811. doi: 10.1161/JAHA.118.010811.
Background Hypertension is the most prevalent and leading risk factor for stroke. SPRINT (The Systolic Blood Pressure Intervention Trial) assessed the effects on cardiovascular event risk of intensive compared with standard systolic blood pressure reduction. In this secondary analysis of SPRINT data, we investigated how low on-treatment diastolic blood pressure ( DBP ) influenced risk for stroke events. Methods and Results For this analysis, we used SPRINT _ POP (Primary Outcome Paper) Research Materials from the National Heart, Lung and Blood Institute (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center. Data for 8944 SPRINT participants were analyzed from the period after target blood pressure was achieved until the end of the trial. Overall, there were 110 stroke events, including 49 from the intensive-treatment arm and 61 in the standard-treatment group. In participants with DBP <70 mm Hg, stroke risk was higher than with DBP ≥70 mm Hg (hazard ratio, 1.467; 95% CI 1.009-2.133; P=0.0445). Univariable Cox proportional hazard risk analysis showed that in the whole group, age and cardiovascular and chronic renal diseases were stroke risk factors. These risk factors were related to lower DBP and higher pulse pressure, however, not to study arm. Multivariable Cox proportional hazard analysis revealed that only age, history of cardiovascular disease, current smoking status and on-treatment systolic blood pressure were significantly related to stroke risk. Conclusions Low on-treatment DBP is not related to the risk for the first stroke, in contrast to older age, the history of cardiovascular disease, current smoking status, and on-treatment systolic blood pressure. Clinical Trial Registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT 01206062.
高血压是中风最常见和主要的危险因素。SPRINT(收缩压干预试验)评估了强化与标准收缩压降低相比对心血管事件风险的影响。在 SPRINT 数据的这项二次分析中,我们研究了治疗中舒张压(DBP)的高低如何影响中风事件的风险。
对于这项分析,我们使用了来自美国国立心肺血液研究所(NHLBI)生物标本和数据存储库信息协调中心的 SPRINT _ POP(主要研究结果论文)研究材料。对 8944 名 SPRINT 参与者在达到目标血压后直至试验结束期间的数据进行了分析。总体而言,有 110 例中风事件,其中强化治疗组 49 例,标准治疗组 61 例。在 DBP<70mmHg 的参与者中,中风风险高于 DBP≥70mmHg 的参与者(风险比,1.467;95%CI,1.009-2.133;P=0.0445)。单变量 Cox 比例风险分析显示,在整个组中,年龄和心血管疾病及慢性肾病是中风的危险因素。这些危险因素与较低的 DBP 和较高的脉压相关,但与研究组无关。多变量 Cox 比例风险分析显示,只有年龄、心血管疾病史、当前吸烟状况和治疗中的收缩压与中风风险显著相关。
与年龄较大、心血管疾病史、当前吸烟状况和治疗中的收缩压相比,治疗中较低的 DBP 与首次中风的风险无关。
https://www.clinicaltrials.gov。唯一标识符:NCT 01206062。